Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Vaccines

MG María Emilia Gaillard
DB Daniela Bottero
MZ María Eugenia Zurita
FC Francisco Carriquiriborde
PA Pablo Martin Aispuro
EB Erika Bartel
DS David Sabater-Martínez
MB María Sol Bravo
CC Celina Castuma
DH Daniela Flavia Hozbor
request Request a Protocol
ask Ask a question
Favorite

The maternal immunization protocols were performed with the three-valent pertussis aP BOOSTRIX® (GSK, GlaxoSmithKline), with composition per human dose (HD): pertussis toxoid (8 µg), pertactin (2.5 µg), filamentous hemagglutinin (8 µg), tetanic toxoid (20 IU), and diphtheria toxoid (2 IU). For all experiments, immunization was carried out through the use of a 1/10 HD of that vaccine, hereafter referred to as a mouse dose (MD). The vaccinations of infant mice were performed with 1 MD of the aP, a commercial wP vaccine (DTP vaccine, PT. BIO FARMA, Indonesia), or the B. pertussis-outer-membrane-vesicle-based vaccine formulated by us as previously described (24), to be referred to as the OMV vaccine.

Copyright and License information:  ©2017 Gaillard, Bottero, Zurita, Carriquiriborde, Martin Aispuro, Bartel, Sabater-Martínez, Bravo, Castuma and Hozbor.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A